Atazanavir sulfate

Molecular foimula C38H52N6O7.H2O4S Molecular weight 802.93 CAS Registry No 229975-97-7 

Sample preparation Condition each well of a 3M Empore C2-SD 96 well plate with 250 [iL MeOH and 500 xL 0.1% acetic acid, do not allow to go dry. Add 50 p,L 200 ng/mL IS in MeOH water 60 40 to 200 xL MeOHiwater 60 40 containing 5 million cells, sonicate for 10 min, centrifuge at 2600 g for 10 min. Evaporate the supernatant to dryness, reconstitute with 50 [xL MeOH, add 200 xL water, add 250 p.L 0.1% acetic acid, mix, add to a well on the SPE plate, allow to pass through under vacuum over 2 min, wash with 500 lL 0.1% acetic acid, dry under vacuum for 2 min, elute twice with 200 m-L portions of MeCN MeOH 50 50, pulling to dryness after each portion. Evaporate the eluate to dryness under a stream of nitrogen at 60 over ca. 40 min, reconstitute the residue with 200 LL mobile phase, vortex, inject a 20 aL aliquot. 

Mobile phase MeCN MeOH water 88% formic acid 30 30 40 0.025 

Detector MS, Sciex API 3000 turbo ionspray, electrospray, positive mode at 400, m/z 705 to 335, lonSpray 4600 V, declustering potential 56 V, entrance potential —10 V, focusing potential 220 V, Turbolon gas nitrogen 8 L/min, collision energy 42 V, collision cell exit potential 24 V, dwell time 500 ms, pause time 5 ms 

Whigan, D. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC) practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis, J.Chromatogr.B, 2003, 795, 273 - 289. 

---

Reyataz (Atazanavir sulfate). Bristol-Myers Squibb Pharmaceuticals Ltd. UK Summary of product characteristics, April 2007. 

E N A public statement. Important new pharmacddmtic data demonstmtii that REYATAZ (atazanavir sulfate) combined with NORVIR (ritonavir) and omepmzole should not be co-a inistered. London, 21 December 2004. Available at htQ) //www.emea.eu.int/pdfs/human/fress/pus/20264904eapdf (accessed 21/08/07). 

Bristol-Myers Squibb Company. Re Reyataz (atazanavir sulfate) with or without Norvir (ritonavir) and proton pump inhibitors should not be coadm inister important new pharmacokinetic data, December 2004. Available at htq> //www. fda.gov/oashi/aids/listserv/ 2004/reyataz.pdf (accessed 21/08/07). 

Hodder S, Bristol-Myers Squibb Company, Klein R, Struble K, FDA. Letter to health care providers. Re Important new pharmacokinetic data for REYATAZ (atazanavir sulfate) in combination with Viread (tenofovir disoproxil fumarate). August 8, 2003. Available at http //www.fda.gOv/oashi/aids/listserve/listserve2003.html (accessed 21/08/07). 

Prescribing information for atazanavir sulfate (Reyataz) capsules (2004) Bristol-Myers Squibb, Princeton... 

---